Search

Search Constraints

You searched for: Author/Creator Foard, Darren

Search Results

1. A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year. (16th March 2017)

2. Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis. (18th November 2018)

3. Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers. (24th May 2019)

4. Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis. Issue 7 (1st March 2023)

5. Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real‐world longitudinal data. (29th June 2021)

6. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens. (13th June 2014)

7. Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light‐chain amyloidosis. (29th January 2023)

8. Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. (2nd September 2021)

9. Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis. Issue 20 (28th June 2022)

10. Six-minute walk test (6MWT) in AL amyloidosis – baseline and 12-month follow-up after chemotherapy. (16th March 2017)